Immunotherapy in triple-negative breast cancer: A literature review and new advances

Valencia, Guillermo; Rioja, Patricia; Morante, Zaida; Ruiz, Rossana; Fuentes, Hugo; Castañeda, Carlos A.; Vidaurre, Tatiana; Neciosup, Silvia P.; Gómez, Henry

doi:10.5306/wjco.v13.i3.219

Cited by 22 publications

(26 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Breast cancer is a heterogeneous disease, comprised of different molecular subtypes. Patients with triple-negative breast cancer (TNBC) have the worst prognosis, largely due to aggressive tumour behaviour, increased risk of metastasis, and resistance to conventional anti - cancer therapies (55). Treatments which target the TME in TNBC have gained increased attention in recent years, spurred on by data demonstrating the strong immunogenicity of this tumour type (56) and success of combined chemotherapy and immunotherapy in clinical trials (57, 58).…”

Section: Resultsmentioning

confidence: 99%

Tunable PhenoCycler Imaging of the Murine Pre-Clinical Tumour Microenvironments

Abraham,

Goncalves,

McCallum

et al. 2023

Preprint

View full text Add to dashboard Cite

The tumour microenvironment (TME) consists of tumour-supportive immune cells, endothelial cells, and fibroblasts. PhenoCycler, a high-plex single cell imaging platform, is used to characterize the complexity of the TME. Here, we used PhenoCycler to spatially resolve the TME of 8 routinely employed pre-clinical models of lymphoma, breast cancer, and melanoma. Our data reveal distinct TMEs in the different cancer models that were imaged, and show that cell-cell contacts differ depending on the tumour type examined. For instance, we found that the immune infiltration in a murine model of melanoma is altered in cellular organization in melanomas that become resistant to αPD-1 therapy, with depletions in a number of cell-cell interactions. Furthermore, we provide detailed pipelines for the conjugation of antibodies that are optimized for PhenoCycler staining of murine FFPE tissues specifically, alongside open-source data analysis procedures. Overall, this is a valuable resource study seamlessly adaptable to any field of research involving murine models.

show abstract

Section: Resultsmentioning

confidence: 99%

Tunable PhenoCycler Imaging of the Murine Pre-Clinical Tumour Microenvironments

Abraham,

Goncalves,

McCallum

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Despite the significant and promising results shown in clinical trials for immunotherapy, some reviews have pointed out that PD-L1 is not the ideal biomarker to be used in patients’ selection for anti-PD-L1/anti-PD-1 therapies and the prediction of responses to immunotherapy [ 131 , 132 , 133 ]. Other biomarkers are currently under investigation, such as tumor mutational burden, the presence of tumor-infiltrating lymphocytes, microsatellite instability, LDH levels, the presence of visceral disease, major histocompatibility complex, the detection of circulating tumor DNA, the value of CD274 amplifications, and immune gene expression profiles [ 131 , 132 , 133 , 134 ]. Despite of the search for new and better biomarkers, other forms of immunotherapy are also currently under investigation, which include vaccines, adoptive cell therapies, autologous tumor-infiltrating lymphocytes, oncolytic virus therapies, and cytokine agents [ 14 , 133 , 135 ].…”

Section: Current Landscape Of Precision-medicine Therapy For Tnbcmentioning

confidence: 99%

“…Auristatin E was tested in a randomized phase II clinical trial (EMERGE). In recent years, FDA approval has been granted to certain ADC drugs for the treatment of BC and TNBC, which may be a potential approach for the treatment of BC and TNBC in the clinic ( Table 3 ) [ 14 , 50 , 127 , 128 , 129 , 129 , 130 , 131 , 132 , 196 , 197 ].…”

Section: Clinical Trials Status In Metastatic Bc and Tnbcmentioning

confidence: 99%

Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type

Subhan

Parveen

Shah

et al. 2023

Cancers

View full text Add to dashboard Cite

Breast cancer is a heterogeneous disease with different molecular subtypes. Breast cancer is the second leading cause of mortality in woman due to rapid metastasis and disease recurrence. Precision medicine remains an essential source to lower the off-target toxicities of chemotherapeutic agents and maximize the patient benefits. This is a crucial approach for a more effective treatment and prevention of disease. Precision-medicine methods are based on the selection of suitable biomarkers to envision the effectiveness of targeted therapy in a specific group of patients. Several druggable mutations have been identified in breast cancer patients. Current improvements in omics technologies have focused on more precise strategies for precision therapy. The development of next-generation sequencing technologies has raised hopes for precision-medicine treatment strategies in breast cancer (BC) and triple-negative breast cancer (TNBC). Targeted therapies utilizing immune checkpoint inhibitors (ICIs), epidermal growth factor receptor inhibitor (EGFRi), poly(ADP-ribose) polymerase inhibitor (PARPi), antibody–drug conjugates (ADCs), oncolytic viruses (OVs), glucose transporter-1 inhibitor (GLUT1i), and targeting signaling pathways are potential treatment approaches for BC and TNBC. This review emphasizes the recent progress made with the precision-medicine therapy of metastatic breast cancer and TNBC.

show abstract

“…Cancer vaccines, as another option, can be generated from killing or modifying cancer cells removed during surgery in the lab and used as personalized vaccines to strengthen the immune response to control cancer growth, eliminate residual tumor cells, or convey long-term immune memory 13 , 14 . Immunotherapy is now emerging as an important component in the therapeutic management of TNBC 15 .…”

Section: Introductionmentioning

confidence: 99%

Targeting myeloid-derived suppressor cells in combination with tumor cell vaccination predicts anti-tumor immunity and breast cancer dormancy: an in silico experiment

Mehdizadeh

Shariatpanahi

Goliaei

et al. 2023

Sci Rep

View full text Add to dashboard Cite

Among the different breast cancer subsets, triple-negative breast cancer (TNBC) has the worst prognosis and limited options for targeted therapies. Immunotherapies are emerging as novel treatment opportunities for TNBC. However, the surging immune response elicited by immunotherapies to eradicate cancer cells can select resistant cancer cells, which may result in immune escape and tumor evolution and progression. Alternatively, maintaining the equilibrium phase of the immune response may be advantageous for keeping a long-term immune response in the presence of a small-size residual tumor. Myeloid-derived suppressor cells (MDSCs) are activated, expanded, and recruited to the tumor microenvironment by tumor-derived signals and can shape a pro-tumorigenic micro-environment by suppressing the innate and adaptive anti-tumor immune responses. We recently proposed a model describing immune-mediated breast cancer dormancy instigated by a vaccine consisting of dormant, immunogenic breast cancer cells derived from the murine 4T1 TNBC-like cell line. Strikingly, these 4T1-derived dormant cells recruited fewer MDSCs compared to aggressive 4T1 cells. Recent experimental studies demonstrated that inactivating MDSCs has a profound impact on reconstituting immune surveillance against the tumor. Here, we developed a deterministic mathematical model for simulating MDSCs depletion from mice bearing aggressive 4T1 tumors resulting in immunomodulation. Our computational simulations indicate that a vaccination strategy with a small number of tumor cells in combination with MDSC depletion can elicit an effective immune response suppressing the growth of a subsequent challenge with aggressive tumor cells, resulting in sustained tumor dormancy. The results predict a novel therapeutic opportunity based on the induction of effective anti-tumor immunity and tumor dormancy.

show abstract

Immunotherapy in triple-negative breast cancer: A literature review and new advances

Cited by 22 publications

References 65 publications

Tunable PhenoCycler Imaging of the Murine Pre-Clinical Tumour Microenvironments

Tunable PhenoCycler Imaging of the Murine Pre-Clinical Tumour Microenvironments

Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type

Targeting myeloid-derived suppressor cells in combination with tumor cell vaccination predicts anti-tumor immunity and breast cancer dormancy: an in silico experiment

Contact Info

Product

Resources

About